• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Foot Locker, Ross Stores, Palo Alto Networks, And Other Big Gainers From Friday

    11/21/22 4:37:32 AM ET
    $AMBA
    $APLS
    $ARDX
    $ATAI
    Semiconductors
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMBA alert in real time by email

    U.S. stocks closed higher on Friday, with the Dow Jones gaining around 200 points. Here is the list of some big stocks recording gains in the previous session.

    • Clearfield, Inc. (NASDAQ:CLFD) shares climbed 26.7% to close at $117.94 after the company reported better-than-expected Q4 results.
    • IVERIC bio, Inc. (NASDAQ:ISEE) shares surged 25.6% to close at $21.65 after the company announced the FDA has granted breakthrough therapy designation for avacincaptad pegol for geographic atrophy.
    • NWTN Inc. (NASDAQ:NWTN) rose 23.9% to close at $5.08.
    • Ardelyx, Inc. (NASDAQ:ARDX) gained 20.9% to close at $2.08. Ardelyx recently announced the FDA Advisory Committee voted 9-to-4 that the benefits of XPHOZAH outweigh its risks for the control of serum phosphorus in adult patients with chronic kidney disease on dialysis.
    • DLocal Limited (NASDAQ:DLO) climbed 20.6% to settle at $12.78 as the stock rebounded after falling Wednesday following a short report issued by Muddy Waters Research.
    • Sculptor Capital Management, Inc. (NYSE:SCU) gained 17.2% to close at $9.95. Sculptor Capital Management's independent Directors announced formation of special committee to explore potential transactions.
    • StoneCo Ltd. (NASDAQ:STNE) climbed 16.8% to settle at $11.53 after the company reported Q3 results.
    • Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) gained 16.7% to close at $50.45 after the company announced FDA acceptance of the company's NDA amendment and new PDUFA date of February 26, 2023 for pegcetacoplan for geographic atrohpy.
    • Atkore Inc. (NYSE:ATKR) gained 15.3% to close at $116.00 after the company posted upbeat Q4 results and issued strong Q1 earnings forecast.
    • Evolent Health, Inc. (NYSE:EVH) gained 14.7% to close at $27.36. Evolent Health agreed to acquire NIA (also known as Magellan Specialty Health), the specialty benefit management organization owned by Centene.
    • Ambarella, Inc. (NASDAQ:AMBA) jumped 14.2% to close at $76.35.
    • indie Semiconductor, Inc. (NASDAQ:INDI) rose 14.1% to close at $7.69. Indie Semiconductor priced $140 million aggregate principal amount of its 4.500% Convertible Senior Notes due 2027 via a private institutional offering.
    • Nutex Health Inc. (NASDAQ:NUTX) gained 13.3% to close at $1.19.
    • Ross Stores, Inc. (NASDAQ:ROST) climbed 9.9% to settle at $107.59 after the company reported better-than-expected Q3 results and issued strong earnings guidance.
    • Angel Pond Holdings Corporation (NYSE:POND) gained 9.8% to close at $10.12.
    • New Oriental Education & Technology Group Inc. (NYSE:EDU) jumped 9.8% to close at $29.08.
    • Atai Life Sciences N.V. (NASDAQ:ATAI) rose 9.6% to settle at $3.07.
    • Design Therapeutics, Inc. (NASDAQ:DSGN) surged 9.5% to close at $15.06. Design Therapeutics recently posted Q3 loss of $0.32 per share.
    • Foot Locker, Inc. (NYSE:FL) gained 8.7% to close at $35.88 after the company reported better-than-expected Q3 adjusted EPS and sales results and raised FY22 guidance.
    • Ryan Specialty Holdings, Inc. (NYSE:RYAN) rose 8.4% to close at $37.51. Patrick G Ryan, Chief Executive Officer at Ryan Specialty Holdings, reported a large insider buy on November 17, according to a new SEC filing
    • The Gap, Inc. (NYSE:GPS) rose 7.6% to close at $13.67 after the company reported better-than-expected Q3 sales results.
    • Matthews International Corporation (NASDAQ:MATW) gained 7.5% to settle at $30.01 following upbeat Q4 results.
    • Palo Alto Networks, Inc. (NASDAQ:PANW) rose 7% to close at $167.48 after the company reported better-than-expected results for its second quarter and issued strong FY23 earnings guidance. The company also announced plans to acquire Cider Security for approximately $195 million.
    • Open Lending Corporation (NASDAQ:LPRO) gained 6.4% to close at $7.14. Open Lending’s Board Of Directors authorized $75 million share repurchase program.
    Get the next $AMBA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMBA
    $APLS
    $ARDX
    $ATAI

    CompanyDatePrice TargetRatingAnalyst
    AtaiBeckley Inc.
    $ATAI
    3/27/2026$12.00Buy
    Deutsche Bank
    Ryan Specialty Holdings Inc.
    $RYAN
    3/17/2026$45.00Outperform
    RBC Capital Mkts
    Design Therapeutics Inc.
    $DSGN
    3/16/2026$15.00Buy
    Jefferies
    Apellis Pharmaceuticals Inc.
    $APLS
    3/13/2026$31.00Buy
    Roth Capital
    Ross Stores Inc.
    $ROST
    3/4/2026$220.00 → $240.00Market Perform → Outperform
    Telsey Advisory Group
    Palo Alto Networks Inc.
    $PANW
    3/3/2026$185.00Sell → Buy
    Arete
    Ryan Specialty Holdings Inc.
    $RYAN
    2/25/2026$43.00Outperform → Market Perform
    BMO Capital Markets
    Evolent Health Inc
    $EVH
    2/25/2026Overweight → Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $AMBA
    $APLS
    $ARDX
    $ATAI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

    10/20/23 4:37:52 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

    10/18/23 4:43:04 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XPHOZA™ issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZA™ (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

    10/18/23 4:37:08 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMBA
    $APLS
    $ARDX
    $ATAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer-Healthcare Montgomery Pamela W. bought $7,021 worth of shares (79 units at $88.87), increasing direct ownership by 3% to 2,758 units (SEC Form 4)

    4 - Nutex Health Inc. (0001479681) (Issuer)

    3/16/26 3:02:43 PM ET
    $NUTX
    Real Estate

    Director Ryan Patrick G Jr bought $1,033,975 worth of shares (25,865 units at $39.98), increasing direct ownership by 0.14% to 256,559 units (SEC Form 4)

    4 - RYAN SPECIALTY HOLDINGS, INC. (0001849253) (Issuer)

    2/24/26 5:15:41 PM ET
    $RYAN
    Specialty Insurers
    Finance

    Director Mott David M bought $1,946,331 worth of shares (333,333 units at $5.84), increasing direct ownership by 11% to 3,302,918 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    2/23/26 9:01:11 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMBA
    $APLS
    $ARDX
    $ATAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    StoneCo Ltd. to Announce First Quarter 2026 Financial Results on May 14th, 2026

    George Town, Grand Cayman--(Newsfile Corp. - April 2, 2026) - StoneCo Ltd. (NASDAQ:STNE) ("Stone") today announces that it will release its first quarter 2026 financial results on Thursday, May 14th, 2026, after the market closes. The Company will also host a conference call to discuss its results on the same day at 5:00pm ET (6:00pm BRT).The conference call can be accessed live over the Zoom webinar (ID: 811 4841 9160 | Password: 164760). You can also access the meeting over the phone by dialing +1 646 931 3860 or +1 669 444 9171 from the U.S. Callers from Brazil can dial +55 21 3958 7888. Callers from the UK can dial +44 330 088 5830. The call will also be webcast live and a replay will be

    4/2/26 7:31:00 AM ET
    $STNE
    EDP Services
    Technology

    Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx

    WALTHAM, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the appointment of Rajani Dinavahi, MD, as Chief Medical Officer (CMO). Dr. Dinavahi brings more than two decades of experience in healthcare and biotechnology, spanning multiple therapeutic areas and modalities. She has extensive experience across immuno-oncology, autoimmune diseases, metabolic disease, nephrology and transplantation, with a track record of advancing programs from early development through Phase 3 and regulatory approval. Dr. Dinavahi m

    4/1/26 8:01:00 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    dLocal to Report First Quarter 2026 Financial Results

    MONTEVIDEO, Uruguay, March 31, 2026 (GLOBE NEWSWIRE) -- DLocal Limited (NASDAQ:DLO, "dLocal" or the "Company")), a leading financial technology company powering payments across emerging markets, intends to release financial results for its first fiscal quarter ended March 31, 2026 on May 14, 2026 after market close. The Company will host a conference call and video webcast on May 14, 2026 at 6:00 p.m. Eastern Time. Please click here to pre-register for the conference call and obtain your dial in number and passcode. The live conference call can be also accessed via audio webcast at the investor relations section of the Company's website, at https://investor.dlocal.com/. An archive of the

    3/31/26 4:10:02 PM ET
    $DLO
    Real Estate

    $AMBA
    $APLS
    $ARDX
    $ATAI
    SEC Filings

    View All

    SEC Form SC TO-C filed by Apellis Pharmaceuticals Inc.

    SC TO-C - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    4/3/26 5:10:30 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Ross Stores Inc.

    144 - ROSS STORES, INC. (0000745732) (Subject)

    4/2/26 4:22:32 PM ET
    $ROST
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Design Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Design Therapeutics, Inc. (0001807120) (Filer)

    4/1/26 4:03:31 PM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMBA
    $APLS
    $ARDX
    $ATAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Deutsche Bank initiated coverage on AtaiBeckley with a new price target

    Deutsche Bank initiated coverage of AtaiBeckley with a rating of Buy and set a new price target of $12.00

    3/27/26 8:46:10 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on Ryan Specialty Group with a new price target

    RBC Capital Mkts initiated coverage of Ryan Specialty Group with a rating of Outperform and set a new price target of $45.00

    3/17/26 9:29:57 AM ET
    $RYAN
    Specialty Insurers
    Finance

    Jefferies initiated coverage on Design Therapeutics with a new price target

    Jefferies initiated coverage of Design Therapeutics with a rating of Buy and set a new price target of $15.00

    3/16/26 8:40:28 AM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMBA
    $APLS
    $ARDX
    $ATAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Paul Josh D.

    4 - Palo Alto Networks Inc (0001327567) (Issuer)

    4/3/26 4:30:29 PM ET
    $PANW
    Computer peripheral equipment
    Technology

    SEC Form 4 filed by Golechha Dipak

    4 - Palo Alto Networks Inc (0001327567) (Issuer)

    4/3/26 4:30:26 PM ET
    $PANW
    Computer peripheral equipment
    Technology

    SEC Form 3 filed by new insider Dinavahi Rajani

    3 - ARDELYX, INC. (0001437402) (Issuer)

    4/3/26 4:16:22 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMBA
    $APLS
    $ARDX
    $ATAI
    Leadership Updates

    Live Leadership Updates

    View All

    Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx

    WALTHAM, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the appointment of Rajani Dinavahi, MD, as Chief Medical Officer (CMO). Dr. Dinavahi brings more than two decades of experience in healthcare and biotechnology, spanning multiple therapeutic areas and modalities. She has extensive experience across immuno-oncology, autoimmune diseases, metabolic disease, nephrology and transplantation, with a track record of advancing programs from early development through Phase 3 and regulatory approval. Dr. Dinavahi m

    4/1/26 8:01:00 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evolent announces appointment of Archie Mayani as chief product officer

    Industry veteran brings track record of innovation from GHX, Change Healthcare, UnitedHealth Group and Amazon.WASHINGTON, March 19, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced the appointment of health care technology leader and AI innovator Archie Mayani as chief product officer (CPO).Mayani brings more than two decades of leadership experience across health care, enterprise platforms, and AI, with a history of building products that improve clinical and business outcomes at scale.Before joining Evolent, she served as CPO at GHX, where she helped pioneer AI-powered capabilitie

    3/19/26 8:45:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Foodsmart Appoints Cityblock Health Co-Founder and CEO Dr. Toyin Ajayi to Board of Directors

    National leader in value-based care joins as Foodsmart scales foodcare for Medicaid populationsSAN FRANCISCO, March 18, 2026 /PRNewswire/ -- Foodsmart, the leading telenutrition and foodcare provider nationwide, today announced the appointment of Dr. Toyin Ajayi to its Board of Directors. A board-certified Family Medicine physician and the co-founder and CEO of Cityblock Health, Dr. Ajayi brings deep experience serving Medicaid and dually eligible populations through value-based care models designed to improve outcomes and lower total cost of care. For millions of Americans, foo

    3/18/26 9:11:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $AMBA
    $APLS
    $ARDX
    $ATAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.

    SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 4:16:13 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Apellis Pharmaceuticals Inc.

    SC 13G - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 8:47:59 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by indie Semiconductor Inc.

    SC 13G/A - indie Semiconductor, Inc. (0001841925) (Subject)

    11/14/24 4:32:45 PM ET
    $INDI
    Semiconductors
    Technology

    $AMBA
    $APLS
    $ARDX
    $ATAI
    Financials

    Live finance-specific insights

    View All

    StoneCo Ltd. to Announce First Quarter 2026 Financial Results on May 14th, 2026

    George Town, Grand Cayman--(Newsfile Corp. - April 2, 2026) - StoneCo Ltd. (NASDAQ:STNE) ("Stone") today announces that it will release its first quarter 2026 financial results on Thursday, May 14th, 2026, after the market closes. The Company will also host a conference call to discuss its results on the same day at 5:00pm ET (6:00pm BRT).The conference call can be accessed live over the Zoom webinar (ID: 811 4841 9160 | Password: 164760). You can also access the meeting over the phone by dialing +1 646 931 3860 or +1 669 444 9171 from the U.S. Callers from Brazil can dial +55 21 3958 7888. Callers from the UK can dial +44 330 088 5830. The call will also be webcast live and a replay will be

    4/2/26 7:31:00 AM ET
    $STNE
    EDP Services
    Technology

    dLocal to Report First Quarter 2026 Financial Results

    MONTEVIDEO, Uruguay, March 31, 2026 (GLOBE NEWSWIRE) -- DLocal Limited (NASDAQ:DLO, "dLocal" or the "Company")), a leading financial technology company powering payments across emerging markets, intends to release financial results for its first fiscal quarter ended March 31, 2026 on May 14, 2026 after market close. The Company will host a conference call and video webcast on May 14, 2026 at 6:00 p.m. Eastern Time. Please click here to pre-register for the conference call and obtain your dial in number and passcode. The live conference call can be also accessed via audio webcast at the investor relations section of the Company's website, at https://investor.dlocal.com/. An archive of the

    3/31/26 4:10:02 PM ET
    $DLO
    Real Estate

    Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

    Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE® FDA-approved in geographic atrophy, an immune-mediated retinal diseaseBringing together Biogen and Apellis' commercialization capabilities will maximize the potential of both EMPAVELI® and SYFOVRE®, while Apellis' talent and expertise will accelerate Biogen's entry into nephrology and augment launch readiness for felzartamab, currently in Phase 3Acquisition is expected to bolster Biogen's near-and long-term growth prospects, adding immediate revenue from two products with significant growth potential; 2025 n

    3/31/26 6:59:00 AM ET
    $APLS
    $BIIB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)